Brief: Metavant, Poxel Announce Positive Topline Safety, PK/PD Results Of Imeglimin

Poxel SA

09/07/2019 06:07

July 9 (Reuters) - Poxel SA  POXEL.PA :
    * METAVANT AIMS TO INITIATE A PHASE 3 PROGRAM IN PATIENTS WITH TYPE 2
DIABETES AND
CHRONIC KIDNEY DISEASE (CKD) STAGES 3B/4 IN US AND EUROPE 
    * METAVANT AND POXEL ANNOUNCE POSITIVE TOPLINE SAFETY AND PK/PD RESULTS OF
IMEGLIMIN IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE STAGES
3B/4
    * TRIAL MET ITS PRIMARY OBJECTIVE WITH IMEGLIMIN OBSERVED TO HAVE A
FAVORABLE
SAFETY AND TOLERABILITY PROFILE IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC
KIDNEY DISEASE STAGES 3B/4
    * THESE RESULTS FOLLOW TWO POSITIVE READOUTS FOR PHASE 3 TRIALS IN JAPAN
CONDUCTED
BY POXEL AND SUMITOMO DAINIPPON PHARMA
    * PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) DATA ARE CONSISTENT WITH
PREVIOUS POXEL DATA

Source text for Eikon:  ID:nBw1sy1N3a 
Further company coverage:  POXEL.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))